$9.17
1.33% yesterday
Nasdaq, May 20, 09:51 pm CET
ISIN
US91678A1079
Symbol
UPB
Sector
Industry

Upstream Bio Stock price

$9.13
-0.58 5.97% 1M
-8.88 49.31% 6M
-7.31 44.46% YTD
-7.87 46.29% 1Y
-7.87 46.29% 3Y
-7.87 46.29% 5Y
-7.87 46.29% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.08 0.88%
ISIN
US91678A1079
Symbol
UPB
Sector
Industry

Key metrics

Market capitalization $491.14m
Enterprise Value $22.52m
P/B ratio (TTM) P/B ratio 1.10
Cash position $431.38m
P/E forward negative
P/S forward 302.75
EV/Sales forward 13.88

Is Upstream Bio a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Upstream Bio Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Upstream Bio forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Upstream Bio forecast:

Buy
100%

Financial data from Upstream Bio

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
0.57 0.57
-
100%
- Direct Costs 0.04 0.04
-
7%
0.52 0.52
-
91%
- Selling and Administrative Expenses 6.70 6.70
-
1,175%
- Research and Development Expense 26 26
-
4,526%
-32 -32
-
-5,609%
- Depreciation and Amortization 0.04 0.04
-
7%
EBIT (Operating Income) EBIT -32 -32
-
-5,616%
Net Profit -27 -27
-
-4,784%

In millions USD.

Don't miss a Thing! We will send you all news about Upstream Bio directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Upstream Bio Stock News

Neutral
GlobeNewsWire
about 17 hours ago
WALTHAM, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the appointment of Stacy Price, MS, PMP, as Chief Technology Officer.
Neutral
GlobeNewsWire
15 days ago
– Top-line data from Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps expected in the third quarter of 2025 – – Top-line data from Phase 2 clinical trial of verekitug in patients with severe asthma now expected in the first half of 2026 – – First patient in Phase 2 clinical trial of verekitug in patients with chronic obstructive pulmonary disease to ...
Positive
Seeking Alpha
about one month ago
Upstream Bio's IPO raised ~$293m, focusing on developing verekitug, a unique TSLP receptor antagonist for severe respiratory disorders, now in Phase 2 trials. The company has a strong cash position of $471m, despite a net loss of $63m in 2024, providing a long funding runway. Verekitug's less frequent dosing and good safety profile offer potential advantages, but its success hinges on upcoming ...
More Upstream Bio News

Company Profile

Upstream Bio, Inc. is a clinical-stage biotechnology company, which engages in the development of treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It develops verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin. The company was founded in April 2021 and is headquartered in Waltham, MA.

Head office United States
CEO E. Sutherland
Employees 52
Website www.upstreambio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today